Showing results (81-90 of 288) with videos related to

Sort By:
Pageof 29
Leukemia & Lymphoma|December 25, 2015
Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessmentChristopher R D'Angelo, Masha Kocherginsky, Jennifer Pisano, et al.
Ejhaem|January 27, 2025
CD58 expression does not impact response to inotuzumab ozogamicin in patients with B-cell acute lymphoblastic leukemiaRafael Madero-Marroquin, Ryan W Hunter, Caner Saygin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 23, 2008
Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantationAndrew S Artz, Amittha Wickrema, Shira Dinner, et al.
Leukemia Research|August 7, 2010
High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902Richard M Stone, Barry Moser, Ben Sanford, et al.
Cytotherapy|May 3, 2012
Influence of related donor age on outcomes after peripheral blood stem cell transplantationElie M Richa, Rangesh Kunnavakkam, Lucy A Godley, et al.
Leukemia & Lymphoma|December 15, 2010
T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapseVaishalee P Kenkre, Sarah Horowitz, Andrew S Artz, et al.
Haematologica|November 22, 2011
Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909Hongtao Liu, Jeffrey L Johnson, Greg Koval, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 15, 2011
Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantationKoen van Besien, Wendy Stock, Elizabeth Rich, et al.
Leukemia & Lymphoma|February 20, 2016
Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665Rebecca DeBoer, Gregory Koval, Flora Mulkey, et al.
Leukemia & Lymphoma|August 3, 2018
Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantationChristopher R D'Angelo, Brianna Novitsky, Sang Mee Lee, et al.
Pageof 29